<DOC>
	<DOCNO>NCT02695420</DOCNO>
	<brief_summary>- To evaluate pharmacokinetics ( PK ) omecamtiv mecarbil Japanese subject heart failure ( HF ) reduce ejection fraction ; - To evaluate safety tolerability oral omecamtiv mecarbil</brief_summary>
	<brief_title>Safety , PK , Efficacy Omecamtiv Mecarbil Japanese Subjects With Heart Failure With Reduced Ejection Fraction</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Japanese male female ≥ 20 year ≤ 85 year age History chronic stable HF reduce ejection fraction , define require treatment HF minimum 4 week prior screen Reated HF optimal pharmacological therapy Left ventricular ejection fraction ≤ 40 % screening . Severe uncorrected valvular heart disease Hypertrophic obstructive cardiomyopathy , active myocarditis , constrictive pericarditis , clinically significant congenital heart disease Acute myocardial infarction , unstable angina , persistent angina rest within 30 day prior randomization Systolic BP &gt; 160 mmHg &lt; 90 mmHg , diastolic BP &gt; 90 mmHg , HR &gt; 110 beat per minute ( bpm ) HR &lt; 50 bpm Estimated glomerular filtration rate ( eGFR ) &lt; 30 mL/min/1.73m2 TBL ≥ 2x ULN , ALT AST ≥ 3x ULN Other Exclusion Criteria may apply .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Heart Failure</keyword>
</DOC>